Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | aurora kinase B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | aurora kinase B | 303 aa | 299 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | carboxylesterase 5A | 0.1502 | 1 | 1 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0254 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1502 | 1 | 1 |
Onchocerca volvulus | 0.0254 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.1502 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1502 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.1502 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.1502 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.1502 | 1 | 1 |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0254 | 0 | 0.5 |
Onchocerca volvulus | 0.0254 | 0 | 0.5 | |
Loa Loa (eye worm) | carboxylesterase | 0.1502 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0254 | 0 | 0.5 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0254 | 0 | 0.5 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0254 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.1502 | 1 | 1 |
Onchocerca volvulus | 0.0254 | 0 | 0.5 | |
Echinococcus granulosus | carboxylesterase 5A | 0.1502 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1502 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.1502 | 1 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0254 | 0 | 0.5 |
Onchocerca volvulus | 0.0254 | 0 | 0.5 | |
Onchocerca volvulus | 0.0254 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.0273 uM | Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | = 24.4 uM | Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | = 35 uM | Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after 30 mins by malachite green staining-based assay | ChEMBL. | 25262942 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.